Perspective Therapeutics GAAP EPS of -$0.29 beats by $0.01, revenue of $0.29M beats by $0.12M

* Perspective Therapeutics press release [https://seekingalpha.com/pr/20199058-perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2025-results] (NYSE:CATX [https://seekingalpha.com/symbol/CATX]): Q2 GAAP EPS of -$0.29 beats by $0.01.
* Revenue of $0.29M (-45.3% Y/Y) beats by $0.12M.
* _Cash, cash equivalents and short-term investments of approximately $192M as of June 30, 2025 expected to be sufficient to fund current planned clinical milestones and operational investments into late 2026._

MORE ON PERSPECTIVE THERAPEUTICS

* Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy [https://seekingalpha.com/article/4808062-perspective-therapeutics-giving-us-some-valuable-perspective-on-alpha-emitter-therapy]
* Seeking Alpha’s Quant Rating on Perspective Therapeutics [https://seekingalpha.com/symbol/CATX/ratings/quant-ratings]
* Historical earnings data for Perspective Therapeutics [https://seekingalpha.com/symbol/CATX/earnings]
* Financial information for Perspective Therapeutics [https://seekingalpha.com/symbol/CATX/income-statement]